FDA clears Xtrak's thrombectomy catheter:
This article was originally published in Clinica
Executive Summary
The US FDA has given Xtrak Medical clearance to market its first product - a catheter system for removing blood clots from haemodialysis vascular access grafts. The XTD thrombectomy system is a low-profile, wall-contacting catheter that simultaneously pulverises and removes thrombus from the occluded grafts. A clinical study with the system demonstrated "excellent" technical success and three-month patency rates with very low complications, says the Salem, New Hampshire company. The XTD system is also already CE-marked for sale in Europe.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.